retatrutide type 2 diabetes trial results phase Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people Lilly's triple agonist achieves 16.8%

Mumbai, as a metropolitan hub, is at the forefront of adopting new wellness trends, and peptide therapy is no exception

FOR OZEMPIC IS APPROVED SOURCE: DailyMed

found that tirzepatide led to significant dose-dependent reductions in HbA1c levels when compared to a placebo, once-weekly GLP-1RAs, and basal insulin regimens

Retatrutides safety profile demonstrated tolerable side effects, predominantly gastrointestinal disturbances, underscoring the need for patient guidance and monitoring

It has shown improvements in blood sugar control, blood pressure, and lipid profiles, with significant reductions in hemoglobin A1c (HbA1c) levels indicating better blood sugar management

It also dials down the release of glucagon, a hormone that raises blood sugar